NEKTAR THERAPEUTICS (NKTR)
Health Care · Immunomodulatory biologics / clinical-stage immunotherapy · NASDAQ
Clinical-stage immunotherapy company developing regulatory T cell-targeted treatments for autoimmune diseases and cancer.
What NEKTAR THERAPEUTICS does
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory agents to treat autoimmune diseases, inflammatory diseases, and cancer. The company's pipeline includes rezpegaldesleukin, a potential first-in-class IL-2 receptor agonist designed to stimulate regulatory T cells for autoimmune indications, and NKTR-255 for cancer treatment. Nektar applies deep immunology expertise to identify and advance drug candidates through preclinical and clinical development stages.
Themes: ["autoimmune disease / immunology","regulatory T cell (Treg) therapeutics","atopic dermatitis","alopecia areata","type 1 diabetes","cancer immunotherapy","immuno-oncology"]
Fundamentals
- Price$72.92 as of 2026-07-09 close
- Market cap$2.5B as of 2026-07-10
- 1-year return+212.2% as of 2026-07-09 close
- Net margin-280.8% as of 2026-07-10
- Gross margin+100.0% as of 2026-07-10
- ROE-45.8% as of 2026-07-10
- Debt / equity0.10 as of 2026-07-10
- Revenue growth (YoY)-36.2% as of 2026-07-10
- Revenue CAGR (3y)-15.7% SEC XBRL
- Beta1.13 as of 2026-07-10
Key risks (from latest filing)
["Clinical drug development is a lengthy and uncertain process with no guarantee of successful drug candidates for commercial use","Business is highly dependent on the success of rezpegaldesleukin; failure or delay of this program would significantly harm the company","Company is unprofitable with a -280.8% net margin and revenue decline of -36.24% YoY, creating sustainability concerns"]
Competitors & peers
- Regeneron Pharmaceuticals (REGN)
- Moderna (MRNA)
- Vertex Pharmaceuticals (VERX)
- Biogen (BIIB)
- Bristol Myers Squibb (BMY)
- Juno Therapeutics (acquired by Celgene/BMS)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.